SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Churchill Capital Corp. X is a blank check company, which was created for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was founded by Michael Klein on January 4, 2024 and is headquartered in New York, NY.

Infleqtion Inc. - Ordinary Shares - Class A

Infleqtion Inc.

Infleqtion (INFQ) is trending after completing its SPAC merger and commencing trading on the NYSE, supported by its CEO's appearance on CNBC. The community is highly bullish, viewing it as an undervalued "practical quantum play" compared to peers, with temporary trading accessibility issues on some platforms paradoxically fueling optimism for future volume.

The Wendy’s Co. engages in operating, developing, and franchising a system of quick-service restaurants. It operates through the following segments: Wendy’s U.S., Wendy’s International, and Global Real Estate and Development. The Wendy’s U.S. segment includes the operation and franchising of Wendy’s restaurants in the U.S. The Wendy’s International segment is involved in the operation and franchising of Wendy’s restaurants in countries and territories other than the U.S. The Global Real Estate and Development segment focuses on real estate activity for owned sites and sites leased from third parties. The company was founded by R. David Thomas on November 15, 1969 and is headquartered in Dublin, OH.

Wendy`s Co - Ordinary Shares - Class A

Wendy's Co

Wendy's is trending down sharply after reporting Q4 earnings with a significantly lowered 2026 outlook, intensifying community discussion around its prolonged CEO search, dividend sustainability, and the potential for a short squeeze amidst its current low valuation.

Ocular Therapeutix, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapies for diseases and conditions of the eye. Its product pipeline includes Dextenza, OTX-TP, and OTX-TIC. The company was founded by Amarpreet S. Sawhney and Farhad Khosravi on September 12, 2006 and is headquartered in Bedford, MA.

Ocular Therapeutix Inc

Ocular Therapeutix is highly volatile following mixed reactions to its Phase 3 SOL-1 trial results for AXPAXLI in wet AMD. Despite meeting the primary superiority endpoint against Eylea 2mg and offering a reduced treatment burden, the stock plunged as the community debates the data's competitive strength, while others cite market manipulation and renewed buyout potential.

Compass Pathways Plc is a biotechnology company, which provides mental health care services. It focuses on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. The company was founded by Goldsmith George Jay and Malievskaia Ekaterina in 2016 and is headquartered in London, the United Kingdom.

Compass Pathways Plc - ADR

COMPASS Pathways

Positive Phase 3 trial results for COMPASS Pathways' COMP360 psilocybin therapy for treatment-resistant depression are driving significant conversation, with the company also accelerating commercialization plans. The community is weighing its potential as a first-to-market FDA-approved psychedelic treatment against concerns about market viability and competitive landscape.

ZIM Integrated Shipping Services Ltd. engages in the provision of shipping and logistics services. It offers shipping solutions, including the transportation of out-of-gauge cargo, refrigerated cargo, and dangerous and hazardous cargo. The company was founded on June 7, 1945 and is headquartered in Haifa, Israel.

Zim Integrated Shipping Services Ltd

ZIM Integrated Shipping Services is trending as Hapag-Lloyd's confirmed $35 per share acquisition triggers intense community discussion around the significant arbitrage opportunity and expected continued dividends until the late 2026 closing, despite some concerns over regulatory and geopolitical hurdles.

Velo3D, Inc. operates as a technology company, which engages in developing and manufacturing metal laser sintering printing machines for 3D printing. Its products include assure system, flow software, sapphire printer & sapphire XC. The company was founded by Benyamin Buller in June 2014 and is headquartered in Fremont, CA.

Velo3D Inc

Velo3D is generating significant discussion after securing an $11.5 million full-rate production defense contract and being selected as the U.S. Army's first qualified additive manufacturing vendor for ground vehicle systems. While these defense wins and ongoing partnerships with SpaceX and Anduril excite many about its critical role in advanced manufacturing, the community is also actively debating recent share dilution as a factor in near-term price volatility.

Firefly Aerospace, Inc. engages in the design and manufacture of space launch vehicles. It offers Alpha, Beta, Gamma, and orbital transfer vehicles. The company was founded by Thomas E. Markusic, Mark Watt, and Max Polyakov in January 27, 2017 and is headquartered in Cedar Park, TX.

Firefly Aerospace Inc.

Firefly Aerospace is drawing significant attention from aggressive call buyers anticipating an upcoming Alpha rocket launch, with community discussions also energized by its inclusion in the 'Golden Dome' defense contract and the broader enthusiasm for the burgeoning space sector.

Palo Alto Networks, Inc. engages in the provision of network security solutions to enterprises, service providers, and government entities. It operates through the following geographical segments: the United States, Israel, and Other Countries. The company was founded by Nir Zuk in March 2005 and is headquartered in Santa Clara, CA.

Palo Alto Networks Inc

Palo Alto Networks is trending amidst its latest earnings report and a wave of strategic moves, including the acquisition of AI-powered Koi Security and a significant Google Cloud partnership to secure AI workloads. The community is actively debating whether the recent software sector sell-off, driven by AI disruption fears, unfairly impacts cybersecurity, seeing current valuations as a potential buying opportunity.

JFB Construction Holdings is a commercial and residential real estate construction and development company, which engages in delivering services to commercial and residential markets. It operates through the following segments: Commercial Construction, Residential Construction, and Real Estate Development. The Commercial Construction segment includes all activities related to the construction of commercial properties. The Residential Construction segment focuses on the construction of residential properties including single-family homes and multi-family units. The Real Estate Development segment refers to the acquisition, development, and sale of real estate properties. The company was founded by Joseph F. Basille III on April 9, 2024 and is headquartered in Lantana, FL.

JFB Construction Holdings - Ordinary Shares - Class A

JFB Construction Holdings is experiencing extreme volatility and intense community discussion following its announced $1.5 billion merger with Israeli drone maker XTEND, backed by Eric Trump, pivoting the company into AI-driven autonomous defense robotics. While some see a transformational move into a high-growth sector, others are questioning the unusual business combination, expressing concerns about rapid share price swings, potential dilution from a recent private placement, and allegations of market manipulation.

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Medtronic Plc

Medtronic is trending following its recent earnings report, where a beat on top and bottom lines was overshadowed by softer guidance and margin concerns, leading to a stock dip. Community discussion is also focused on the strategic plan to spin off its diabetes business, coupled with a series of new FDA clearances for advanced medical devices, signaling a potential shift towards higher-growth segments.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Preview: Cytokinetics (CYTK) Q4 Earnings Expected to Decline

Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Can BMY's Growth Portfolio Counter Legacy Drugs Decline in 2026?

BMYs 2025 results highlight a shifting revenue mix as 17% growth in newer drugs offsets legacy declines, with more erosion expected in 2026.

Cytokinetics (CYTK) Expected to Announce Earnings on Tuesday

Cytokinetics (NASDAQ:CYTK) will be releasing its Q4 2025 earnings after the market closes on Tuesday, February 24. (View Earnings Report at...

Bayer's Asundexian Shows 26% Stroke Reduction in Late-Stage Study

Bayer presents positive data on asundexian, which shows superior efficacy with no added bleeding risk, boosting hopes for regulatory approval.

Cytokinetics (NASDAQ:CYTK) EVP Andrew Callos Sells 15,000 Shares

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 15,000 shares of the stock in a transaction dated Thursday, February 5th. The shares were sold at an average price of...

Andrew Callos Sells 15,000 Shares of Cytokinetics (NASDAQ:CYTK) Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 15,000 shares of the firm's stock in a transaction dated Thursday, February 5th. The shares were sold at an average...

Truist Financial Forecasts Strong Price Appreciation for Cytokinetics (NASDAQ:CYTK) Stock

Truist Financial increased their target price on shares of Cytokinetics from $84.00 to $92.00 and gave the stock a "buy" rating in a report on Tuesday...

Insider Selling: Cytokinetics (NASDAQ:CYTK) EVP Sells 886 Shares of Stock

Cytokinetics, Incorporated (NASDAQ:CYTK - Get Free Report) EVP Andrew Callos sold 886 shares of the stock in a transaction on Monday, February 2nd. The shares were sold at an average price of $62.10...

Lisanti Capital Growth LLC Acquires New Position in Cytokinetics, Incorporated $CYTK

Lisanti Capital Growth LLC acquired a new stake in shares of Cytokinetics, Incorporated (NASDAQ:CYTK - Free Report) during the 3rd quarter, according to the company in its most recent 13F filing with...

Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates

Regeneron (REGN) delivered earnings and revenue surprises of +8.32% and +1.77%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Cytokinetics, Inc. is a biopharmaceutical company, which is focused on discovering, developing, and commercializing muscle activators and muscle inhibitors as potential treatments for people with debilitating diseases in which muscle performance is compromised and/or declining. The firm is developing small molecule drug candidates specifically engineered to impact muscle function and contractility. Its clinical-stage drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator, CK-136, a novel cardiac troponin activator, reldesemtiv, a novel fast skeletal muscle troponin activator, aficamten, a novel cardiac myosin inhibitor, and CK-3772271, a novel cardiac myosin inhibitor. The company was founded by Ronald D. Vale, Lawrence S. B. Goldstein, James H. Sabry, and James A. Spudich in 1997 and is headquartered in South San Francisco, CA.

CYTK
Cytokinetics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest CYTK News

CYTKCytokinetics Inc